Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) Share-based Compensation (IS) (2016 - 2025)

Historic Share-based Compensation (IS) for Evogene (EVGN) over the last 13 years, with Q3 2025 value amounting to $27000.0.

  • Evogene's Share-based Compensation (IS) fell 9254.14% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $894000.0, marking a year-over-year decrease of 3252.83%. This contributed to the annual value of $1.2 million for FY2024, which is 3377.73% down from last year.
  • Evogene's Share-based Compensation (IS) amounted to $27000.0 in Q3 2025, which was down 9254.14% from $234000.0 recorded in Q2 2025.
  • Evogene's 5-year Share-based Compensation (IS) high stood at $801000.0 for Q2 2023, and its period low was $27000.0 during Q3 2025.
  • In the last 5 years, Evogene's Share-based Compensation (IS) had a median value of $411000.0 in 2022 and averaged $409368.4.
  • Its Share-based Compensation (IS) has fluctuated over the past 5 years, first soared by 73846.15% in 2023, then crashed by 9254.14% in 2025.
  • Evogene's Share-based Compensation (IS) (Quarter) stood at $737000.0 in 2021, then plummeted by 60.52% to $291000.0 in 2022, then tumbled by 61.17% to $113000.0 in 2023, then soared by 180.53% to $317000.0 in 2024, then tumbled by 91.48% to $27000.0 in 2025.
  • Its Share-based Compensation (IS) was $27000.0 in Q3 2025, compared to $234000.0 in Q2 2025 and $316000.0 in Q1 2025.